在老年不可切除转移性结直肠癌患者中,氟嘧啶/贝伐珠单抗联合或不联合奥沙利铂作为初始治疗:一项多中心、随机、开放标签III期试验(JCOG1018)
JCOG1018研究纳入251例老年不可切除转移性结直肠癌患者,随机分组接受氟嘧啶+贝伐珠单抗或在此基础上联合奥沙利铂。结果显示联合奥沙利铂组中位无进展生存期10.0个月对9.4个月(HR 0.84,单侧P=0.086),未达统计学显著;≥3级不良事件发生率联合组更高(69%对52%)。结论:老年患者一线治疗中加用奥沙利铂未显示获益,推荐氟嘧啶+贝伐珠单抗。
要点
- 在老年(≥70岁)不可切除转移性结直肠癌患者中,氟嘧啶+贝伐珠单抗基础上加用奥沙利铂未显著改善无进展生存期(HR 0.84,单侧P=0.086)。
- 联合奥沙利铂组≥3级不良事件发生率更高(69%对52%),治疗相关死亡分别为3例和1例。
- 对于该老年人群,推荐氟嘧啶+贝伐珠单抗作为一线治疗。
核心结论
- 在老年不可切除转移性结直肠癌患者中,一线氟嘧啶+贝伐珠单抗基础上加用奥沙利铂未显示获益,推荐氟嘧啶+贝伐珠单抗用于该人群。
研究设计与样本
- 多中心、随机、开放标签III期试验(JCOG1018),在日本42家机构开展。
- 纳入70-74岁且ECOG-PS为2分、或≥75岁且ECOG-PS为0-2分的不可切除转移性结直肠癌患者。
- 随机1:1分配至氟嘧啶+贝伐珠单抗组(n=125)或氟嘧啶+贝伐珠单抗+奥沙利铂组(n=126),共251例;入组前声明使用氟尿嘧啶+左亚叶酸钙或卡培他滨。
- 主要终点为无进展生存期(PFS);研究注册于日本临床试验注册库(jRCTs031180145)。
主要发现
- 中位年龄在氟嘧啶+贝伐珠单抗组为80岁,联合奥沙利铂组为79岁。
- 中位PFS在氟嘧啶+贝伐珠单抗组为9.4个月(95%CI 8.3-10.3),联合奥沙利铂组为10.0个月(95%CI 9.0-11.2),HR 0.84(90.5%CI 0.67-1.04),单侧P=0.086。
- 中位总生存期在氟嘧啶+贝伐珠单抗组为21.3个月(95%CI 18.7-24.3),联合奥沙利铂组为19.7个月(95%CI 15.5-25.5),HR 1.05(95%CI 0.81-1.37)。
- 任何≥3级不良事件发生率在联合奥沙利铂组更高(69%对52%)。
- 治疗相关死亡在氟嘧啶+贝伐珠单抗组为1例,联合奥沙利铂组为3例。
关键数值与推荐
- 无进展生存期:氟嘧啶+贝伐珠单抗组9.4个月(95%CI 8.3-10.3)对联合奥沙利铂组10.0个月(95%CI 9.0-11.2),HR 0.84(90.5%CI 0.67-1.04),单侧P=0.086。
- 总生存期:氟嘧啶+贝伐珠单抗组21.3个月(95%CI 18.7-24.3)对联合奥沙利铂组19.7个月(95%CI 15.5-25.5),HR 1.05(95%CI 0.81-1.37)。
- ≥3级不良事件比例:氟嘧啶+贝伐珠单抗组52%对联合奥沙利铂组69%。
- 治疗相关死亡:氟嘧啶+贝伐珠单抗组1例,联合奥沙利铂组3例。
临床怎么用
- 对于老年(70-74岁ECOG-PS 2分或≥75岁ECOG-PS 0-2分)不可切除转移性结直肠癌患者,一线推荐氟嘧啶+贝伐珠单抗,不联合奥沙利铂。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Doublet chemotherapy with fluoropyrimidine (FP) and oxaliplatin (OX) plus bevacizumab (BEV) is a standard regimen for unresectable metastatic colorectal cancer (MCRC). However, the efficacy of adding OX to FP plus BEV (FP + BEV) remains unclear for older patients, a population for whom FP + BEV is standard. We aimed to confirm the superiority of adding OX to FP + BEV for this population. METHODS: This open-label, randomized, phase III trial was conducted at 42 institutions in Japan. Patients with unresectable MCRC age 70-74 years with Eastern Cooperative Oncology Group performance status (ECOG-PS) 2 and those 75 years and older with ECOG-PS 0-2 were randomly assigned (1:1) to an FP + BEV arm or an OX addition (FP + BEV + OX) arm. Fluorouracil plus levofolinate calcium or capecitabine was declared before enrollment. The primary end point was progression-free survival (PFS). The study was registered in the Japan Registry of Clinical Trials (identifier: jRCTs031180145). RESULTS: Between September 2012 and March 2019, 251 patients were randomly assigned to the FP + BEV arm (n = 125) and the FP + BEV + OX arm (n = 126). The median age was 80 and 79 years in the respective arm. The median PFS was 9.4 months (95% CI, 8.3 to 10.3) in the FP + BEV arm and 10.0 months (9.0 to 11.2) in the FP + BEV + OX arm (hazard ratio [HR], 0.84 [90.5% CI, 0.67 to 1.04]; one-sided P = .086). The median overall survival was 21.3 months (18.7 to 24.3) in the FP + BEV arm and 19.7 months (15.5 to 25.5) in the FP + BEV + OX arm (HR, 1.05 [0.81 to 1.37]). The proportion of any grade ≥3 adverse events was higher in the FP + BEV + OX arm (52% v 69%). There was one treatment-related death in the FP + BEV arm and three in the FP + BEV + OX arm. CONCLUSION: No benefit of adding OX to FP + BEV as first-line treatment was demonstrated in older patients with MCRC. FP + BEV is recommended for this population.
引用
- Takashima A, Hamaguchi T, Mizusawa J, et al. Oxaliplatin Added to Fluoropyrimidine/Bevacizumab as Initial Therapy for Unresectable Metastatic Colorectal Cancer in Older Patients: A Multicenter, Randomized, Open-Label Phase III Trial (JCOG1018). J Clin Oncol. 2024. PMID: 39186709. doi:10.1200/JCO.23.02722
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。